trial

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up

NCTId NCT03090503
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 200 (estimated)
Sponsored by Fundación Marques de Valdecilla
Primary completion 2019-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
200 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2014-06
Primary completion
2019-06
Eligibility
ALL · 15 Years · 60 Years

Interventions & indications

Drugs
AripiprazoleRisperidone

Sponsors

Fundación Marques de ValdecillaLead Sponsor
Centro de Investigación Biomédica en Red de Salud MentalCollaborator
Instituto de Investigación Marqués de ValdecillaCollaborator

Investigators

1
Benedicto Crespo-Facorro, ProfessorPrincipal Investigator

Sites

1 total
Santander, Spain

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE4
Primary Completion Date
2019-06
Status
UNKNOWN
relationships
The graph out of here
drug
Aripiprazole
drug
Risperidone
drug
lead_sponsor
Fundación Marques de Valdecilla
company
collaborator
Centro de Investigación Biomédica en Red de Salud Mental
company
Instituto de Investigación Marqués de Valdecilla
company
indication
Psychotic Disorders
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Benedicto Crespo-Facorro, Professor
person